News

ESSA Pharma Adjusts Agreement with XenoTherapeutics for Shareholders

ESSA Pharma Adjusts Agreement with XenoTherapeutics for Shareholders

ESSA Pharma Amends Agreement with XenoTherapeutics

ESSA Pharma Inc. (NASDAQ: EPIX) has recently informed its shareholders of crucial amendments made to its Business Combination Agreement with XenoTherapeutics. This change signals an important step for the company as it navigates its future arrangements.

Key Changes to Shareholder Distributions

As part of the revised agreement, ESSA shareholders can expect to receive approximately US$0.12 per common share in cash upon the successful closing of this transaction. In addition, shareholders are entitled to a contingent value right, representing potential future payments of up to US$0.14 per share. The modifications made to the agreement are primarily based on the consideration of potential liabilities and updated estimates regarding the company’s cash balance.

Details of the Financial Adjustments

The changes in the financial terms are notable given that, under earlier estimates, shareholders were projected to receive around US$1.91 per common share. The latest projections place a focus on the balance of US$1.69 already distributed to shareholders previously. Therefore, the total expected economic benefit per common share is duly adjusted, indicating a strategic response to existing financial circumstances and projected cash flows.

Special Meeting Rescheduled

In connection with the amendments to the agreement, ESSA Pharma has also decided to further adjourn its upcoming special meeting initially scheduled for late September. The meeting is now set to reconvene on October 3, allowing shareholders ample time to review and approve the amended agreement.

Impact of the Meeting on Shareholders

Shareholders who do not wish to change their existing votes on the transaction are not required to take further action at this stage. This consideration helps streamline the participatory process while ensuring that stakeholders remain informed about crucial developments.

Advisory and Legal Support

ESSA Pharma is currently collaborating with Leerink Partners as their exclusive financial advisor. Legal guidance is being provided by two firms: Blake, Cassels & Graydon LLP for Canadian legal matters, and Skadden, Arps, Slate, Meagher & Flom LLP for U.S. legal support. This dual-layer approach ensures comprehensive representation in both jurisdictions during this significant transitional phase for the company.

About ESSA Pharma Inc.

ESSA is a biotechnology firm focused on developing innovative therapies aimed at treating prostate cancer. Through its strategic partnerships and ongoing research, the company continues to position itself at the forefront of cancer treatment solutions, benefiting patients and stakeholders alike.

About XenoTherapeutics

XenoTherapeutics Inc. operates as a 501(c)(3) non-profit research foundation dedicated to the advancement of xenotransplantation. The foundation prioritizes scientific research, clinical development, and education to push the boundaries of organ transplantation.

About XOMA Royalty Corporation

XOMA Royalty focuses on biotechnology, serving as a royalty aggregator with a diverse array of assets related to future economics emerging from therapeutic advancements. Its portfolio reflects the potential for substantial developments that underlie its business model.

Frequently Asked Questions

What is the amendment in ESSA's agreement with XenoTherapeutics?

The amendment includes adjustments to cash payments and contingent value rights for shareholders, reflecting updated estimates and potential liabilities.

When is the special meeting for shareholders reconvening?

The special meeting will reconvene on October 3, allowing shareholders to review and endorse the amended agreement.

Who are the advisors assisting ESSA Pharma?

ESSA Pharma has engaged Leerink Partners for financial advisory services, and legal counsel comes from Blake, Cassels & Graydon LLP and Skadden, Arps, Slate, Meagher & Flom LLP.

What is ESSA Pharma's main focus as a company?

ESSA is dedicated to developing advanced therapies specifically aimed at treating prostate cancer, leveraging innovative research and partnerships.

What does XenoTherapeutics focus on?

XenoTherapeutics is focused on advancing xenotransplantation through research, clinical development, and educational outreach in the field of organ transplantation.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 431

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Sandler Partners Unveils 2025 Superstar Trip Destination

Updated Category News Views 179

Sandler Partners Unveils 2025 Superstar Trip Destination Sandler Partners is thrilled to reveal the highly anticipated location for its 2025 Superstar Trip, a special reward designed to honor Partners who have excelled in achieving their growth objectives for the year. The trip will take place at the stunning Susurros del Corazón Resort, located along the picturesque...

Continue Reading
e.l.f. Beauty Stock Insights: Understanding Market Trends Today

Updated Category News Views 309

Market Sentiment Surrounding e.l.f. Beauty Investors with substantial capital are showing a cautious approach towards e.l.f. Beauty (NYSE: ELF). This sentiment isn't just noise in the market; it reflects deeper strategies that should be on the radar of traders and analysts alike. There has been significant insight gleaned from public options activity which suggests that...

Continue Reading
Empowering Teens Through Free AI Bootcamp by Mark Cuban

Updated Category News Views 216

Empowering Teens Through Innovative AI Bootcamp Time is of the essence for high school students eager to launch their careers in technology with the Mark Cuban Foundation's Artificial Intelligence (AI) Bootcamp. Hosted by Girls Inc., this remarkable initiative opens doors for teens interested in the cutting-edge realm of AI. Applications for participation are set to close...

Continue Reading
BlackRock's Major Acquisition of Global Infrastructure Partners

Updated Category News Views 275

BlackRock Secures $12.5 Billion Deal The U.S. Federal Energy Regulatory Commission has recently approved BlackRock's substantial acquisition of Global Infrastructure Partners, valued at $12.5 billion. This approval is a pivotal moment for BlackRock as it seeks to broaden its reach within the infrastructure investment sector. Details of the Acquisition In this significant...

Continue Reading
Key Analyst Initiations Impacting Major Stocks This Week

Updated Category News Views 120

Recent Analyst Initiations: An Overview In the dynamic realm of stock trading, the insights of analysts can have a major impact on market trends. Recently, Wall Street has made significant adjustments to their ratings for several well-known stocks. Below, we summarize the latest analyst actions that may affect investor decisions this week. Arm Holdings plc (NASDAQ: ARM)...

Continue Reading